Investigating the Therapeutics Effects of Oral Cavity Derived Stem Cells on Neurodegenerative Diseases: A Systematic Review.

IF 2.6 2区生物学 Q2 MYCOLOGY

Mycologia Pub Date : 2023-09-01 DOI:10.32598/bcn.2021.2892.1

Emel Uzunoglu-Ozyurek, Gizem Önal, Serap Dökmeci

{"title":"Investigating the Therapeutics Effects of Oral Cavity Derived Stem Cells on Neurodegenerative Diseases: A Systematic Review.","authors":"Emel Uzunoglu-Ozyurek, Gizem Önal, Serap Dökmeci","doi":"10.32598/bcn.2021.2892.1","DOIUrl":null,"url":null,"abstract":"Introduction: Published data obtained from in vitro and in vivo studies was reviewed systematically and analyzed critically to evaluate the effect of oral cavity-derived stem cells (OCDSCs) on the recovery or therapy of neurodegenerative diseases (NDs), such as Alzheimer disease (AD), amyotrophic lateral sclerosis (ALS), Huntington (HD) diseases, and Parkinson disease (PD).Methods: An electronic search was accomplished. References of included articles were also manually searched. Studies were critically evaluated for suitability against the inclusion/exclusion criteria and the data was extracted. Bias risk evaluation of the studies and evidence synthesis were conducted.Results: A total of 14 in vivo and 10 in vitro studies met the inclusion criteria. PD was induced in 10 in vivo and 7 in vitro studies, while AD was induced in 2 in vivo and 4 in vitro studies. Two studies (1 in vitro and 1 in vivo) evaluated ALS disease and 1 in vivo study evaluated HD. Moderate evidence was found for in vitro studies reporting the positive effect of OCDSCs on PD or AD recovery. Strong evidence was found for in vivo studies in which PD animal models were used; meanwhile, moderate evidence was found for the impact of OCDSCs on AD recovery. Limited evidence was found for in vivo studies evaluating HD and ALS.Conclusion: Although studies reported favorable data regarding the OCDSCs on NDs, they presented a considerable risk of bias. Because of heterogeneous study characteristics, the current study recommends improving standardized methods to evaluate the therapeutic effects of OCDSCs on the NDs.","PeriodicalId":18779,"journal":{"name":"Mycologia","volume":"79 1","pages":"565-584"},"PeriodicalIF":2.6000,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11016878/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Mycologia","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.32598/bcn.2021.2892.1","RegionNum":2,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"MYCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Introduction: Published data obtained from in vitro and in vivo studies was reviewed systematically and analyzed critically to evaluate the effect of oral cavity-derived stem cells (OCDSCs) on the recovery or therapy of neurodegenerative diseases (NDs), such as Alzheimer disease (AD), amyotrophic lateral sclerosis (ALS), Huntington (HD) diseases, and Parkinson disease (PD).

Methods: An electronic search was accomplished. References of included articles were also manually searched. Studies were critically evaluated for suitability against the inclusion/exclusion criteria and the data was extracted. Bias risk evaluation of the studies and evidence synthesis were conducted.

Results: A total of 14 in vivo and 10 in vitro studies met the inclusion criteria. PD was induced in 10 in vivo and 7 in vitro studies, while AD was induced in 2 in vivo and 4 in vitro studies. Two studies (1 in vitro and 1 in vivo) evaluated ALS disease and 1 in vivo study evaluated HD. Moderate evidence was found for in vitro studies reporting the positive effect of OCDSCs on PD or AD recovery. Strong evidence was found for in vivo studies in which PD animal models were used; meanwhile, moderate evidence was found for the impact of OCDSCs on AD recovery. Limited evidence was found for in vivo studies evaluating HD and ALS.

Conclusion: Although studies reported favorable data regarding the OCDSCs on NDs, they presented a considerable risk of bias. Because of heterogeneous study characteristics, the current study recommends improving standardized methods to evaluate the therapeutic effects of OCDSCs on the NDs.

查看原文本刊更多论文

研究口腔干细胞对神经退行性疾病的治疗效果：系统综述。

导言：为了评估口腔干细胞（OCDSCs）对神经退行性疾病（NDs）（如阿尔茨海默病（AD）、肌萎缩性脊髓侧索硬化症（ALS）、亨廷顿病（HD）和帕金森病（PD））的康复或治疗效果，我们对已发表的体外和体内研究数据进行了系统回顾和批判性分析：方法：进行电子检索。方法：进行了电子检索，并对所收录文章的参考文献进行了人工检索。根据纳入/排除标准对研究进行严格评估，并提取数据。对研究进行了偏倚风险评估和证据综合：共有 14 项体内研究和 10 项体外研究符合纳入标准。10项体内研究和7项体外研究诱发了帕金森病，2项体内研究和4项体外研究诱发了注意力缺失症。两项研究（1 项体外研究和 1 项体内研究）对 ALS 疾病进行了评估，1 项体内研究对 HD 进行了评估。报告 OCDSCs 对帕金森病或注意力缺失症康复有积极影响的体外研究发现了中度证据。在使用帕金森病动物模型进行的体内研究中，发现了强有力的证据；同时，在 OCDSCs 对注意力缺失症康复的影响方面，发现了中等程度的证据。评估 HD 和 ALS 的体内研究证据有限：结论：尽管研究报告了有关 OCDSCs 对 NDs 的有利数据，但它们存在相当大的偏倚风险。由于研究特点不尽相同，本研究建议改进标准化方法，以评估 OCDSCs 对 NDs 的治疗效果。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Mycologia 生物-真菌学

CiteScore

6.20

自引率

3.60%

发文量

审稿时长

4-8 weeks

期刊介绍： International in coverage, Mycologia presents recent advances in mycology, emphasizing all aspects of the biology of Fungi and fungus-like organisms, including Lichens, Oomycetes and Slime Molds. The Journal emphasizes subjects including applied biology, biochemistry, cell biology, development, ecology, evolution, genetics, genomics, molecular biology, morphology, new techniques, animal or plant pathology, phylogenetics, physiology, aspects of secondary metabolism, systematics, and ultrastructure. In addition to research articles, reviews and short notes, Mycologia also includes invited papers based on presentations from the Annual Conference of the Mycological Society of America, such as Karling Lectures or Presidential Addresses.